Searchable abstracts of presentations at key conferences on calcified tissues

ba0007p53 | (1) | ICCBH2019

Successful treatment with enzyme replacement therapy in a girl with severe infantile Hypophosphatasia

Heldt Katrin , L'Allemand Dagmar

Background: Infantile Hypophosphatasia (HPP) is an inborn error of metabolism characterized by low serum alkaline phosphatase activity caused by loss-of-function mutations within the ALPL-gene encoding the tissue nonspecific isoenzyme of ALP (TNSALP). TNSALP controls skeletal and dental mineralization by hydrolyzing inorganic pyrophosphate, a potent inhibitor of bone mineralization. Patients develop substantial skeletal disease, failure to thrive, and sometimes vitamin B6&#150...

ba0003pp174 | Cell biology: osteocytes | ECTS2014

Structural analysis of tooth and jawbone in a type 2 diabetes mouse model

Repp Felix , Kollmannsberger Philip , Roschger Andreas , Roschger Paul , Wagermaier Wolfgang , Fratzl Peter , Weinkamer Richard

In type 2 diabetes mellitus (T2DM) patients, an increased fracture risk is observed, although the bone mineral density is even higher than in non-diabetic patients. This raises the question of the quality of the organic and inorganic matrix in bone1–3. T2DM is also known to forward dysfunctions in the development of soft tissues such as brittle skin due to cross-linking of the collagen or inflammation of the gingiva. For the latter, a possible influence of diab...

ba0005p168 | Cell biology: osteoblasts and bone formation | ECTS2016

Two different domains of fibronectin stimulate osteoblast differentiation by activating distinct integrins

Sens Carla , Rau Katrin , Nakchbandi Inaam

Fibronectin is produced in different isoforms by osteoblasts during differentiation. In contrast to the circulating Isoform, which lacks extra domains, the fibronectin laid down by the osteoblasts in the matrix contains one or both extra-domains called EDA and EDB. We had found that deletion of fibronectin in osteoblasts decreased BMD. This is mediated by diminished osteoblast differentiation and cannot be corrected by the circulating isoform of fibronectin, suggesting a role ...

ba0003pp146 | Cell biology: osteoblasts and bone formation | ECTS2014

Strontium ranelate increases osteoblast cell proliferation and differentiation and the formation of bone-like mineralized matrix on different titanium substrates

Querido William , Farina Marcos , Anselme Karine

The integration of biomaterials into the calcified bone tissue is essential for the clinical success of bone implants. A particular strategy to improve such integration is the use of specific molecules to increase osteoblast cell adhesion, proliferation, and/or differentiation on the surface of the implants, aiming to enhance the interaction of cells with biomaterials. The goal of this study was to better understand the potential of the anti-osteoporotic drug strontium ranelat...

ba0001pp94 | Bone development/growth and fracture repair | ECTS2013

The healing of fracture of mandible against the chronic nitrate intoxication

Aveticov David , Kostenko Vitaly , Neporada Karine , Lokes Ekaterina , Stavickiy Stanislav

Damages of bones of facial skeleton lay down 8% from all damages, fractures of mandible are 85–90% from it. There are a lot of factors, that make worse the process of reparative regeneration of bone. Using of nitric fertilizers lead to heighten earning of nitric oxide into organism. It makes negative influence on reparative regeneration of bones.There are dates of research of 40 rats line Vistar in this article. The goal of this study was to examine...

ba0006p124 | (1) | ICCBH2017

The treatment of Hyperphosphatemic Familial Tumoral Calcinosis

Khatchadourian Karine , Lawton Lou , Willis Baxter , Ward Leanne

Background: Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by hyperphosphatemia and the formation of tumor-like extra-osseous calcifications. Tumors often necessitate surgical management although medical treatment may limit the need for surgical intervention. We present two cases of HFTC successfully managed with combination acetazolamide (ACTZ) and sevelamer carbonate.Case Report #1: A 5-year-old African boy with a loss-of-functio...

ba0001pp131 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Effects of zoledronic acid on hormone levels in premenopausal women with breast cancer receiving neoadjuvant or adjuvant chemotherapy and endocrine therapy: Probone II Study

Hadji Peyman , Kauka Anette , Bauer Thomas , Ziller May , Birkholz Katrin , Baier Monika , Muth Mathias , Kann Peter

Introduction: Loss in bone mineral density may occur soon after initiation of adjuvant therapy for hormone-receptor-positive (HR+), breast cancer (BC) and correlates with changes in hormone levels. Adding zoledronic acid (ZOL) to adjuvant treatment for BC can preserve/improve bone mineral density and delay disease recurrence; however, effects of ZOL on endocrine hormone levels are currently unclear.Methods: Probone II assessed the course of endocrine hor...

ba0001pp161 | Cancer and bone: basic, translational and clinical | ECTS2013

Effect of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for breast cancer: the ProBONE II Study

Hadji Peyman , Kauka Anette , Bauer Thomas , Birkholz Katrin , Baier Monika , Muth Mathias Muth , Ziller May

Introduction: Bone mineral density (BMD) evaluations have shown that adjuvant chemotherapy or endocrine therapy (ET) for early breast cancer (BC) is associated with accelerated BMD loss and increased fracture risk. In recent studies, zoledronic acid (ZOL) increased BMD in premenopausal and postmenopausal women with BC, and improved disease-free survival in some patient subsets compared with no ZOL. The purpose of the current study was to investigate the effect of adjuvant trea...

ba0005p455 | Other diseases of bone and mineral metabolism | ECTS2016

An isoform of fibronectin is responsible for bone loss in hepatic osteodystrophy and its deleterious effects can be prevented by binding the mediating receptor

Sens Carla , Rau Katrin , Altrock Eva , Klemis Verena , Tiwari Sanjay , Nakchbandi Inaam

Cholestatic liver disease is often associated with increased fracture risk. We had found that circulating levels of a fibronectin isoform called oncofetal fibronectin (oFN) were elevated in patients with primary biliary cirrhosis. Indeed, injecting oFN to mice suppressed osteoblast differentiation and bone mineral density in vivo, suggesting it is responsible for bone loss in these patients. The aim of this study was to define the mechanism by which oFN affects osteob...